Ferroptosis targeting: a novel therapeutic armamentarium in multiple myeloma
Open Access
- 25 March 2026
- journal article
- review article
- Published by Springer Nature in Cancer Cell International
- Vol. 26 (1)
Abstract
Multiple myeloma (MM), a hematological malignancy characterized by abnormal plasma cell proliferation, remains incurable because of its pervasive resistancKeywords
Funding Information
- Beijing Natural Science Foundation ((No. 7252174))
- Wu Jieping Medical Foundation ((320.6750.2024-13-59))
This publication has 101 references indexed in Scilit:
- Bone marrow stromal cells protect myeloma cells from ferroptosis through GPX4 deSUMOylationCancer Letters, 2024
- Unveiling ferroptosis as a promising therapeutic avenue for colorectal cancer and colitis treatmentActa Pharmaceutica Sinica B, 2024
- Bortezomib elevates intracellular free Fe2+ by enhancing NCOA4-mediated ferritinophagy and synergizes with RSL-3 to inhibit multiple myeloma cellsAnnals of Hematology, 2024
- Novel methyltransferase G9a inhibitor induces ferroptosis in multiple myeloma through Nrf2/HO-1 pathwayAnnals of Hematology, 2024
- Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosisApoptosis, 2023
- Ferritinophagy induced ferroptosis in the management of cancerCellular Oncology, 2023
- Epigenetic modulation of ferroptosis in cancer: Identifying epigenetic targets for novel anticancer therapyCellular Oncology, 2023
- Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and StrokesAdvanced Science, 2023
- Andrographolide induced ferroptosis in multiple myeloma cells by regulating the P38/Nrf2/HO-1 pathwayArchives of Biochemistry and Biophysics, 2023
- Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signalingMedicinal Research Reviews, 2023